Athira Pharma to Participate in Panel and Corporate Presentations at Life Science Innovation Northwest Conference
Athira Pharma (NASDAQ: ATHA) will participate in the virtual Life Science Innovation Northwest Conference on March 30-31, 2021. CEO Leen Kawas will discuss new treatments for Alzheimer's disease and neurodegeneration in a panel at 12:30 p.m. PT on March 30, moderated by Paul Matteis. Kevin Church will present a corporate overview from 1:35 to 3:00 p.m. PT on the same day. Both events will be webcast live. Athira is focused on developing small molecules like ATH-1017 to restore neuronal health and combat neurodegeneration.
- None.
- None.
BOTHELL, Wash., March 23, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that the company will participate in panel and corporate presentations at the virtual Life Science Innovation Northwest Conference taking place March 30-31, 2021.
Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a panel titled “New Treatments and Potential Cures in Alzheimer’s Disease and Neurodegeneration: The Future is Here!” at 12:30 p.m. PT on Tuesday, March 30. The discussion will be moderated by Paul Matteis, Managing Director at Stifel, and include participation from Valerie Daggett, Ph.D., Co-Founder and Chief Executive Officer at AltPep, and Carole Ho, M.D., Chief Medical Officer and Head of Development at Denali Therapeutics.
Kevin Church, Ph.D., will present a corporate overview as part of the Neuroscience & Discovery Platforms company presentations from 1:35 to 3:00 p.m. PT on Tuesday, March 30.
These events will be webcast live and available for access by registered conference attendees. For more information on registration, please visit: https://lifesciencewa.org/events/life-science-innovation-northwest/
About Athira Pharma, Inc.
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.
Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219
FAQ
What is the date of Athira Pharma's participation in the Life Science Innovation Northwest Conference?
Who will represent Athira Pharma at the Life Science Innovation Northwest Conference?
What time will the panel discussion on Alzheimer's disease take place?
What is the focus of Athira Pharma's therapeutic candidate ATH-1017?
Is the conference presentation by Athira Pharma available for public viewing?
